Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Charles Schwab Corporation Common Stock — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Charles Schwab Corporation Common Stock trades at $98.05 (market cap $165.91B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 170.5× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Charles Schwab Corporation Common Stock pays a 1.33% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Charles Schwab Corporation Common Stock for 86 Days on average.
| MRVI | SCHW | |
|---|---|---|
Market Cap | $972.90M | $165.91B |
Volume | 4,325,710 | 6,860,399 |
Sector | Health | Financials |
52-Week High | $9.00 | $113.65 |
52-Week Low | $2.83 | $85.35 |
Typical Hold Time | 0 Days | 86 Days |
Enterprise Value | $1.08B | $152.35B |
Dividend Yield | — | 1.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Charles Schwab (SCHW) trades at $96.80, down 0.27% on the day, with technical indicators showing bearish momentum despite strong fundamental performance. The company reported record quarterly revenue of $7.08 billion in Q3 2026 and has beaten earnings estimates for three consecutive quarters. Analyst consensus remains bullish with a $120.69 price target, representing 25% upside potential from current levels.
SCHW demonstrates robust financial health with 38.79% net margins and 22.45% ROE, though technical weakness and competitive pressures in brokerage services present near-term challenges. The stock offers attractive valuation at 17.48x P/E with strong earnings momentum, but investors should monitor interest rate sensitivity and market volatility impacts on trading volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
